SPAC Voyager to combine with Veraxa Biotech at ~$1.5B enterprise value; close expected Q4 2025

Voyager Acquisition Corp./Cayman Islands

Pro forma combined enterprise value of ~$1.5B; Veraxa shareholders roll over 100% of equity.
Transaction funded by $253M SPAC trust cash and $25M PIPE; closing anticipated in Q4 2025.
Pro forma ownership: Veraxa 78.6%, SPAC public 15.9%, Sponsor 4.0%, PIPE investors 1.6%.
Combined company to trade on Nasdaq; tickers: VACHU (units), VACH (shares), VACHW (warrants).

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.